Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients

NCT06956144 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 113

Last updated 2025-05-29

No results posted yet for this study

Summary

To evaluate the efficacy of targeted CAIX-specific probe PET imaging in the diagnosis and staging of kidney cancer, as well as to assess its role in prognosis prediction and treatment evaluation for kidney cancer.

Conditions

  • Tumor
  • Carbonic Anhydrase IX

Sponsors & Collaborators

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-09
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06956144 on ClinicalTrials.gov